AstraZeneca shares fall 4% to 7-1/2 week low
LONDON (Reuters) -Shares in London-listed drugmaker AstraZeneca fell more than 4% on Monday, sliding to their lowest since July 19.
Three analysts and one AstraZeneca shareholder told Reuters they attributed the move to a report in the Mail on Sunday newspaper saying that the drugmaker’s Chief Executive Pascal Soriot had said privately to friends and advisers that he may leave the company as soon as next year.
Reuters could not independently verify the information.
An AstraZeneca spokesperson declined to comment on the report.
Two of the analysts and the shareholder also mentioned that an article published on Monday in Britain’s Times newspaper could have affected the shares, though it appeared to contradict the Mail on Sunday report.
The Times’ article focused on the retirement of Mene Pangalos, the long-time biopharmaceuticals head of research at AstraZeneca, which was announced in July. In it, Pangalos was quoted as saying: ““Pascal has got a lot of years ahead of him and he works as hard and as intensely as he did when I first met him in 2012.”
(Reporting by Maggie Fick and Samuel Indyk; Editing by Amanda Cooper and Tomasz Janowski)
Why pay for news and opinions when you can get them for free?
Subscribe for free now!
NEWS2 days ago
Heavy winter sweaters, coats pile up at stores as warm weather threatens holiday shopping season
NEWS3 days ago
Oil jumps 3% as steep US crude stocks draw adds to supply concerns
INVESTING3 days ago
3 Ways to Revolutionize Retail Trading
NEWS3 days ago
Sizes of European government debt trades halve in 2023-ICMA